Formulation: A lyophilized powder
Formal Name: L-tyrosyl-3-mercapto-D-valylglycyl-L-phenylalanyl-3-mercapto-D-valine, cyclic (2→5)-disulfide, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C30H39N5O7S2 • XCF3COOH
Formula Weight: 645,8
Shelf life (days): 1460
Notes: DPDPE is a synthetic enkephalin peptide and an agonist of δ1-opioid receptors (Ki = 2.7 nM for the rat receptors).{37712} It is selective for δ-opioid receptors over μ- and κ-opioid receptors (Kis = 713 and >1,500 nM, respectively, for the rat receptors). In vivo, DPDPE (4.5 nmol i.c.v.) increases the latency to tail withdrawal in the tail flick test in mice, an effect that can be reversed by the δ1-opioid receptor antagonist [D-Ala2,Leu5,Cys6]enkephalin (DALCE) but not the δ2-opioid receptor antagonist natrindole-5'-isocynate.{37712,67604} DPDPE (140 nmol, i.c.v) increases the seizure threshold in a rat model of flurothyl-induced seizures and is protective against seizures induced by maximal electroshock (MES) in rats.{37713} It reduces formalin-induced paw licking in rats in a dose-dependent manner.{37714} In vivo, DPDPE (15 µg, i.c.v.) increases latency to tail withdrawal in wild-type, δ-opioid receptor knockout (DOR-/-), and μ-opioid receptor knockout (MOR-/-) mice, but the latter effect can be prevented by the μ-opioid receptor antagonist CTOP (Item No. 27377).{37715}
English
Deutsch
